Abstract |
Cis-diamminedichloroplatinum (II) (cis-Pt) complexed to a carboxymethyl dextran- avidin conjugate was targeted to biotin- monoclonal antibody 108 (b-MAb 108). This MAb recognizes the extracellular domain of the epidermal growth factor receptor ( EGF-R) on human epidermoid carcinoma (KB) cells over-expressing EGF-R. Cis-Pt- carboxymethyl-dextran- avidin (Pt-dex-Av) containing 60-90 M cis-Pt/M avidin was administered 24 hr following b-MAb108 containing 3-5 M biotin/M MAb. This treatment was potentially more effective in suppressing the growth of established KB tumor xenografts, or in inhibiting the development of lung metastases in nude mice, than free MAb 108, free drug or MAb 108 followed by drug. Replacing b-MAb 108 by unbiotinylated antibody or by b-MAb of a different specificity also yielded lower suppressive effects. The sequential administration of Pt-dex-Av following b-MAb was more effective than introduction of the Pt-dex-Av when already complexed to b-MAb 108. The results presented in this preliminary investigation suggest that Pt-dex-Av is specifically removed from the circulation by b-MAb 108 concentrated at the tumor site.
|
Authors | B Schechter, R Arnon, M Wilchek, J Schlessinger, E Hurwitz, E Aboud-Pirak, M Sela |
Journal | International journal of cancer
(Int J Cancer)
Vol. 48
Issue 2
Pg. 167-72
(May 10 1991)
ISSN: 0020-7136 [Print] United States |
PMID | 1708362
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Neoplasm
- Dextrans
- Drug Carriers
- Avidin
- Biotin
- carboxymethyl dextran
- Cisplatin
|
Topics |
- Animals
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Neoplasm
(administration & dosage)
- Avidin
- Biotin
- Cisplatin
(administration & dosage)
- Combined Modality Therapy
- Dextrans
- Drug Administration Schedule
- Drug Carriers
- Humans
- KB Cells
(drug effects)
- Lung Neoplasms
(prevention & control, secondary)
- Mice
- Mice, Nude
- Neoplasm Transplantation
|